Impact of a Self-rehabilitation and Tele-rehabilitation Program on the Post-stroke Care Pathway

Ischemic Stroke Clinical Trial

— AUTONHOME  

Official title:

AUTONHOME: Impact of a Self-rehabilitation and Tele-rehabilitation Program on the Post-stroke Care Pathway : Preliminary Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06443840
• Other study ID #: 2023-A01298-37
• Status: Recruiting
• Phase: N/A
• Start date: May 6, 2024
• Est. completion date: March 2026

Study information

• Verified date: May 2024
• Source: Association APPROCHE
• Contact: Marie-Caroline Delebecque, CRA
• Phone: 0297826174
• Email: approche[@]mutualite29-56.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The AutonHome® clinical investigation, proposed by Dr Charles FATTAL (coordinator of this study), and carried out by the Association Approche (delegated promoter), aims to use the AutonHome® selfeducation device for the rehabilitation of patients who have suffered a Cerebrovascular Accident (CVA), and thus respond to the problems of therapeutic discontinuity highlighted today. Neuradom's AutonHome® device combines self-education and telecare. This device makes it possible to carry out personalised self-education programmes supervised by the therapist, enabling the therapeutic link with the patient to be maintained without the need for the patient to travel. This tool has already proved its usability and perceived usefulness in a previous clinical study, which demonstrated the feasibility of a self-education programme for hemiplegic patients, based on feedback. AutonHome® was considered by users to be a relevant, useful and safe complement to conventional rehabilitation.

On the basis of this feasibility study, the investigators wished to develop a second study around this AutonHome® device. In this second clinical investigation, in addition to perceived usefulness, the main objective is to demonstrate, in a population of stroke victims, that an experimental care pathway combining supervised self-education via AutonHome® with conventional re-education optimises the care pathway in terms of sensory-motor recovery, but also in terms of reduced length of stay and functional and medico-economic added value.

This clinical trial involves two parallel arms. Participants will be randomised into a control group, undergoing conventional in-centre rehabilitation, or into an experimental group, with self-rehabilitation and tele-rehabilitation in addition to conventional rehabilitation. The AutonHome study is a pilot study, with the aim of including 40 participants. Each centre will recruit 10 participants on a 1:1 randomisation basis, with 5 in the experimental group and 5 in the control group. Participants will be monitored for 15 weeks. This clinical investigation is multicentre, with 4 centres involved: the Centre Bouffard Vercelli (66962, Perpignan), the CMRRF de Kerpape (56275 Ploemeur), the association Saint-Hélier (35043, Rennes), and the Fondation ILDYS (29684 Roscoff).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 2026
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Participants who signed the written consent form to participate in the study after free and informed information

• Participants affiliated to a social security scheme (beneficiary or beneficiary) outside the AME.

• 18 years = age = 85 years,

• 1st recent ischemic or hemorrhagic unilateral cortico-subcortical hemispheric stroke

• Minimum post-stroke delay: 7 days

• Maximum post-stroke delay : 30 days

• SOFMER category 2: moderate strokes called category 2 according to SOFMER with an NIHSS (initial score of the National Institute of Health Stroke Scale) between 5 and 14 (Several deficiencies or motor deficit of the lower limb prohibiting walking, with recovery potential, a probable autonomy project (unilateral stroke).

• MoCA > 23

Exclusion Criteria:

• Participant deprived of liberty (by judicial or administrative decision)

• Adult participant subject to a legal protection measure or unable to express their consent

• Participation in another ongoing clinical trial

• Pregnant or breastfeeding women or women of childbearing age without effective contraception

• Lack of command of the oral and written French language

• Pre-existing neurological pathology

• Severe expression disorders (expression aphasia) affecting intelligibility

• Severe comprehension disorders (comprehension aphasia)

• Major cognitive disorders of the dementia or post-dementia type

• Unstable psychiatric disorders

• Unstabilized medical pathology

• Unbalanced epilepsy

• Color blindness

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke

Intervention

Device:
• AutonHome® device
The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.

Locations

Country	Name	City	State
France	Fondation Ildys	Brest	Bretagne
France	Centre Bouffard Vercelli - USSAP	Perpignan	Pyrénées-Orientales
France	CMRRF de Kerpape	Ploemeur	Bretagne
France	Association Saint-Hélier	Rennes	Bretagne

Sponsors (3)

Lead Sponsor	Collaborator
Association APPROCHE	IMT Atlantique Brest, Société Neuradom

Country where clinical trial is conducted

France, 

References & Publications (1)

RAOULT, Bérengère, PONTIER, Joanna, FICHEUX, Gilles and FATTAL, Charles, 2020. Étude de faisabilité d'un parcours d'auto-rééducation de patients hémiplégiques. Kinésithérapie Scientifique. Décembre 2020. No. 626, p. 5-13.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the non-inferiority of the experimental course of care, on the technical platform and at home, on the evolution of sensory-motor recovery, compared to the control course.	Change in Fugl-Meyer score between inclusion on Day 0 and the visit on Day 45 (Week 6) Minimum = 0 Maximum = 100; However, as an exploratory secondary endpoint (objective 1a), the sub-scores for the upper limb (UL) and lower limb (LL) will be studied separately, as well as changes at 12 weeks (D80) and 15 weeks (D105).; Upper limb / 66; Lower limb / 34 Total / 100; The higher the Fugl Meyer score, the better the sensory-motor recovery. The Fugl Meyer scores will then be compared between the experimental course (on the technical platform and at home) and the control course.	At 0 and 6 weeks
Secondary	Evaluate the recovery of overall functional independence.	Functional independence measure - MIF; Independence : 7: Complete independence (appropriate to circumstances and safe) 6: Modified independence (device, adaptation); Modified dependence : 5: Supervision 4: Minimal assistance (autonomy = 75% +) 3 : Average assistance (autonomy = 50% +); Complete dependence 2 : Maximum assistance (autonomy = 25% +); If an item cannot be checked, tick level 1.; At the end of the test, we obtain a score ranging from 18 to 126. The lower the score, the greater the disability.	At 0, 6, 12 and 15 weeks
Secondary	The recovery of a seated and standing postural balance, walking and mobility on the plane.	Berg balance scale : The Berg balance assessment scale was developed to measure static and dynamic balance in adults.; This scale comprises 14 tasks rated from 0 to 4, assessing both static and dynamic balance. The total score ranges from 0 to 56 points. The higher the score, the better the assessment of balance.	At 0, 6, 12 and 15 weeks
Secondary	The recovery of a seated and standing postural balance, walking and mobility on the plane.	6min walk test (6MWT) : The six-minute walk test (6MWT) is an objective assessment of functional physical ability. It measures the distance covered by the patient when walking briskly for 6 minutes.; The 6MWT provides a global assessment of various organ functions, in particular the cardiopulmonary, vascular and neuromuscular systems.; Distance covered: The distance covered during the test is the main parameter measured. In general, a longer distance indicates better functional capacity. Here are some approximate reference values: Normal: Approximately 400 to 700 metres. Poor: Less than 300 metres. Very good: Over 800 metres.	At 0, 6, 12 and 15 weeks
Secondary	The recovery of a seated and standing postural balance, walking and mobility on the plane.	10-metre walk test (10MWT) : The 10-metre walk test is an assessment tool that measures a patient's walking speed.; It aims to calculate the speed at which a patient can walk a distance of 10 metres.; The walking speed obtained can be used to classify the patient into different categories: Less than 0.4 m/s: Walking at home. Between 0.4 and 0.8 m/s: Limited walking in the community. More than 0.8 m/s: Unlimited walking in the community.	At 0, 6, 12 and 15 weeks
Secondary	Achievement of objectives	GAS (Goal Attainment Scaling) : The GAS is a tool for defining specific, individualised objectives for each patient. These objectives are then evaluated in a standardised way, allowing statistical analysis of the results.; At least 3 objectives are set and scored between -3 (regression), -2 (much less), -1 (a little less), 0 (expected result), +1 (a little more), +2 (much more).	At 0, 6, 12 and 15 weeks
Secondary	Autonomy and social participation	IPA Scale (Impact on Participation and Autonomy Questionnaire) : Level of participation perceived by the participant through 32 items spread over 5 domains related to autonomy in activities inside the home (7 items), family roles (7 items), activities outside (5 items), social life and relationships (7 items), work and education (6 items). The last 6 are excluded. Score from 0 (very low level of participation) to 4 (very high level).; Level of perception of participation restriction: Score of 0 (major problem), 1 (minor problem), 2 (no problem).	At 0, 6, 12 and 15 weeks
Secondary	The risk of adverse effects	Number of falls	Every day during 15 weeks
Secondary	The risk of adverse effects	Number of moderate or serious adverse events during the session	Every day during 15 weeks
Secondary	The risk of adverse effects	Visual Analog Pain Scale: Intensity and sites of pain before or during and after the session	Every day during 15 weeks
Secondary	The perception of the effort at each session	Borg scale : The Borg scale is generally rated from 6 to 20. The higher the number, the more intense the perceived effort.	Every day during 15 weeks
Secondary	The perceived experience of the session.	Perceived experience of the rehabilitation session in response to the following 4 questions with a scoring that comes in 5 different levels depending on the question : What is the patient's perception of the rehabilitation session offered? Very poor - Poor - No effect - Positive - Very positive; What is the patient's perception of the quality of the exercises proposed? Very poor - Poor - No effect - Positive - Very positive; What is the patient's perception of the intensity of the exercises proposed? Very poor - Poor - No effect - Positive - Very positive; What is the patient's perception of the motivating nature of the exercises proposed? Very poor - Poor - No effect - Positive - Very positive	Every day during 15 weeks
Secondary	The perceived experience of the session.	SIMS MOTIVATION Scale ("Situation Motivation Scale") : The aim is to determine which type of motivation regulates an individual's behaviour during an activity.; 16 items are evaluated: Items 1, 5, 9 and 13 relate to intrinsic motivation (best type of regulation, strong feeling of autonomy).; Items 2, 6, 10 and 14 relate to identified regulation (good type of regulation, high sense of autonomy).; Items 3, 7, 11 and 15 refer to external regulation (poor type of regulation, low sense of autonomy).; Items 4, 8, 12 and 16 relate to motivation (no regulation).	Every day during 15 weeks
Secondary	Compliance with and duration of sessions and stays.	Compliance (present at the session) : Yes/No	Every day during 15 weeks
Secondary	Compliance with and duration of sessions and stays.	Duration of each session (in minutes)	Every day during 15 weeks
Secondary	Compliance with and duration of sessions and stays.	Duration of stay in complete hospitalisation (in days)	Every day during 15 weeks
Secondary	Compliance with and duration of sessions and stays.	Duration of stay in partiel hospitalisation (in days)	Every day during 15 weeks
Secondary	Compliance with and duration of sessions and stays.	Duration of use at home (in days)	Every day during 15 weeks
Secondary	Study the medium-term appropriation of the selfrehabilitation system by the participants.	SUS (System Usability Scale) : only for the experimental groups. The SUS consists of 10 questions in the form of statements. Each question uses a Likert scale, where the user chooses between 5 possible answers, ranging from 'Strongly disagree' to 'Strongly agree'. The answers to the 10 questions are used to construct a satisfaction score, ranging from 1 to 100. In general, a score of 75 or more is considered 'good', while between 50 and 75 it is considered 'fair' or 'correct'. A score of less than 50 indicates major problems in terms of customer satisfaction.	At 0, 6, 12 and 15 weeks
Secondary	Compare the costs of the experimental care pathway to the costs of a conventional care pathway	Study of direct and indirect costs	Every day during 15 weeks